Intel stock extends gains after report of possible U.S. government stake
Wednesday, H.C. Wainwright analysts adjusted their outlook on Genmab (CSE:GMAB) A/S (NASDAQ:GMAB), lowering the 12-month price target to $35 from the previous $37, while retaining a Buy rating on the stock. According to InvestingPro data, the stock appears undervalued at its current price of $19.31, trading at an attractive P/E ratio of 10.58. The revision follows Genmab’s first-quarter financial performance, which surpassed analyst expectations. Genmab reported a diluted net income of $3.05 per share for the first quarter of 2025, outperforming the forecasted $1.98 per share.
The company’s revenue for the quarter was $715 million, with DARZALEX royalties contributing $450 million. This royalty figure fell slightly short of the analysts’ projection of $454 million. Research and Development (R&D) expenses for the quarter were reported at $359 million, and Selling, General, and Administrative (SG&A) expenses at $126 million, both coming in under the anticipated $387 million and $144 million, respectively.
H.C. Wainwright has also updated its full-year net earnings projection for Genmab, raising it to $15.72 from the previous estimate of $14.60. The company concluded the first quarter with approximately $3,226 million in cash, cash equivalents, and marketable securities, maintaining a healthy current ratio of 5.34. Analysts cite DARZALEX’s continued strong performance and Genmab’s robust pipeline as key factors underpinning the company’s solid position in the market, particularly in the multiple myeloma (MM) treatment space. Want deeper insights? InvestingPro offers exclusive access to 10+ additional ProTips and a comprehensive research report for Genmab, along with detailed financial metrics and expert analysis.
The firm’s analysts underscored Genmab’s ability to navigate the challenges within the biotech sector, highlighting its consistent profitability, strong financial foundation, and potential for clinical data catalysts in the near to medium term. This is reflected in the company’s impressive revenue growth of 51.92% over the last twelve months. Despite anticipating higher operating expenses going forward, H.C. Wainwright reaffirms their positive stance on Genmab shares, albeit with a slightly reduced price target.
In other recent news, Genmab A/S announced several developments that are of interest to investors. The company reported a series of share buy-back transactions as part of its capital allocation strategy, detailed in filings with the U.S. Securities and Exchange Commission. These transactions occurred over several weeks, including April 14 to April 18, April 28 to May 2, and May 5 to May 9, 2025. The buy-back program aims to adjust Genmab’s capital structure and meet obligations from share-based incentive programs. Additionally, H.C. Wainwright & Co. maintained a Buy rating on Genmab shares with a $37 price target, citing strong first-quarter sales for the DARZALEX franchise, which reported net sales of $3,237 million. The firm noted that DARZALEX’s performance closely matched their projections and highlighted Genmab’s robust balance sheet and profitability. Genmab’s ongoing commitment to share buy-backs and its strong market presence in multiple myeloma treatments reflect its confidence in long-term growth prospects. Investors can access detailed information about these buy-back transactions and sales figures in the company’s SEC filings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.